Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02FYE
|
||||
Former ID |
DIB009405
|
||||
Drug Name |
TT-223
|
||||
Synonyms |
E1-INT; GLP1-INT; Islet cell neogenesis therapy, Transition Therapeutics; Islet neogenesis therapy, Transition; Diabetes therapy, Waratah/MGH; EGF-INT, Transition Therapeutics; Glucagon-like peptide + gastrin analog, Transition; INT (diabetes), Waratah/MGH; Epidermal growth factor analog + TT-223 (diabetes), Transition; Islet neogenesis therapy (GLP-1, gastrin), Transition; Glucagon-like peptide + TT-223, (diabetes) Transition
|
||||
Indication | Type 1 diabetes [ICD9: 250; ICD10:E10] | Phase 2 | [522421] | ||
Company |
Waratah Pharmaceuticals Inc
|
||||
Target and Pathway | |||||
Target(s) | Gastrin/cholecystokinin type B receptor | Target Info | Modulator | [525743] | |
PANTHER Pathway | CCKR signaling map ST | ||||
PathWhiz Pathway | Gastric Acid Production | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.